发明公开
EP0483077A2 A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas.
失效
Kontrazeptives und menstruzeszyklusregulierendesPräparatmit onkostatischen Eigenschaften。
- 专利标题： A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas.
- 专利标题（中）： Kontrazeptives und menstruzeszyklusregulierendesPräparatmit onkostatischen Eigenschaften。
-
申请号： EP91830402.3申请日： 1991-09-27
-
公开(公告)号： EP0483077A2公开(公告)日： 1992-04-29
- 发明人: Fraschini, Franco, I.F.L.O. S.a.s. , Duranti, Ermanno, I.F.L.O. S.a.s. , Di Bella, Luigi, I.F.L.O. S.a.s. , Stankov, Bojidar, I.F.L.O. S.a.s. , Laguzzi, Aldo, I.F.L.O. S.a.s.
- 申请人： I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi
- 申请人地址： Via Prandina, 7 I-20127 Milano IT
- 专利权人： I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi
- 当前专利权人： I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi
- 当前专利权人地址： Via Prandina, 7 I-20127 Milano IT
- 代理机构： Cicogna, Franco
- 优先权： IT2159690 19900928; IT2233890 19901211; ITMI912438 19910916
- 主分类号： A61K31/565
- IPC分类号： A61K31/565 ; A61K31/57 ; C07D209/30 ; C07D457/02
摘要：
The present invention relates to a drug for human use, having contraceptive and menstrual cycle controlling properties, characterized in that the said drug comprises N-acetyl-5-methoxytryptamine or melatonin, in a dose of 100-200 mg pro die, N-acetyl-2-bromo-5-methoxytryptamine or 2-bromomelatonin in a dose of 25-50 mg pro die N-acetyl-2-iodo-5-methoxytryptamine or 2-iodomelatonin, in a dose of 20-40 mg pro die, in association with a progestinic compound.
The administration is carried out for 23 days, by using an association of 2-iodomelatonin and/or melatonin and/or 2-bromomelatonin and a progestinic compound, followed by 5 days in which only 2-iodomelatonin and/or melatonin and/or 2-bromomelatonin is administered; the drug having oncostatic preventive and therapeutic properties, in mammary tumours and melanomas, characterized by the use of 2-iodomelatonin, melatonin and 2-bromomelatonin respectively with doses of 20-40 mg, 100-200 mg, 25-50 mg pro die; and the said drug having moreover antikinetosic properties, and being characterized by the use of 2-iodomelatonin in a dose pro die of 2.5 mg, melatonin, in a dose pro die of 10 mg and 2-bromomelatonin in a dose pro die of 3.5 mg, either individually and/or in association with the acetyl coenzime A-(AcCoA), in a dose of 8-10 mg pro die.
The administration is carried out for 23 days, by using an association of 2-iodomelatonin and/or melatonin and/or 2-bromomelatonin and a progestinic compound, followed by 5 days in which only 2-iodomelatonin and/or melatonin and/or 2-bromomelatonin is administered; the drug having oncostatic preventive and therapeutic properties, in mammary tumours and melanomas, characterized by the use of 2-iodomelatonin, melatonin and 2-bromomelatonin respectively with doses of 20-40 mg, 100-200 mg, 25-50 mg pro die; and the said drug having moreover antikinetosic properties, and being characterized by the use of 2-iodomelatonin in a dose pro die of 2.5 mg, melatonin, in a dose pro die of 10 mg and 2-bromomelatonin in a dose pro die of 3.5 mg, either individually and/or in association with the acetyl coenzime A-(AcCoA), in a dose of 8-10 mg pro die.
公开/授权文献
信息查询
